ST. LOUIS, Feb. 2 /PRNewswire-FirstCall/ -- Sigma-Aldrich , a member of The RNAi Consortium (TRC), is pleased to introduce the first available shRNA gene family set in lentiviral format for direct use in gene silencing. The MISSION TRC shRNA Human Tumor Suppressor Gene Family is the first in a series of shRNA target sets that allow for rapid RNAi cell-based screens in mammalian systems not easily manipulated by traditional siRNA. The lentiviral transduction particle format eliminates the need to propagate bacterial cells, purify plasmid DNA or undertake the lengthy process of preparing virus, thus saving time and valuable resources. Lentiviral-based shRNA can be used to create a stable knockdown in almost any mammalian cell type, including primary and non-dividing cells.
"Understanding the role of tumor suppressors in cancer biology and drug response is a key factor of cancer research. This collection will enhance drug discovery screens and provide insight into the mechanisms of tumor progression," said Christina Bailey, Global Strategic Market Manager, Functional Genomics "The tumor suppressors assembled in this set are ideal for high-throughput screens and the establishment of stable knockdown cell lines."
The MISSION TRC shRNA Human Tumor Suppressors are also available as bacterial glycerol stocks. This gene family is the second of its kind in the MISSION TRC product offering. The shRNA Human Kinase set in glycerol format was recently released, consisting of 630 kinase targets. Additional gene family sets are anticipated over the next few months.
Sigma-Aldrich is committed to advancing functional genomics through the expansion of gene family sets targeting major research areas. These leading scientific products are backed by a broad portfolio of exclusive intellectual property and have been developed utilizing the Company's state-of-the-art, high throughput lentiviral production center.
Learn more about the MISSION TRC shRNA products at http://www.sigma-aldrich.com/rnai .
About TRC: TRC is comprised of principal investigators from world-class academic research institutions (Massachusetts Institute of Technology, Harvard Medical School, the Broad Institute, Whitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Massachusetts General Hospital, Washington University, Columbia University, and Academia Sinica) as well as corporate sponsoring institutions (Sigma-Aldrich, Novartis, Eli Lilly, and Bristol-Myers Squibb). As a scientific collaborator and distribution partner through agreement with MIT, Sigma-Aldrich is working with TRC to provide the scientific community with RNAi tools for functional genomics research specifically for gene function discovery and the study of disease. The MISSION TRC shRNA clone libraries will comprise a comprehensive collection of 150,000 pre-cloned lentiviral-based shRNA vector constructs targeting 15,000 human genes (MISSION TRC-Hs1.0) and 15,000 mouse genes (MISSION TRC-Mm1.0). Design and development of the TRC libraries is being led by the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard. For more information about MISSION shRNA clone collections, please visit us online at http://sigma-aldrich.com/rnai .
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 35 countries and has over 6,800 employees providing excellent service worldwide. We are committed to accelerating Customer success through leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning Web site at http://www.sigma-aldrich.com .
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding Company operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.
Photo: http://www.newscom.com/cgi-bin/prnh/20050215/CGSIGMAALLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSigma-AldrichCONTACT: Keith Jolliff of Sigma-Aldrich, +1-314-289-8484
